Growth hormone receptor antagonist mice: longer median and maximal lifespan
In an abstract, a lab reports that transgenic mice with disrupted growth hormone receptor action lived longer at median and maximum, and 2-year-old mice were less frail with stronger grip despite more body fat. [1]
Automatic summary · not editorially reviewed
The key findings
Pegvisomant binds rodent growth hormone receptors poorly, so it has not been tested for lifespan extension in rodents; the authors instead studied GHA transgenic mice. [1]
Median and maximal lifespan were significantly increased in male and female GHA mice, with maximal lifespan extended by 186 days in males and 265 days in females. [1]
In a separate cohort of 2-year-old mice, GHA males and females were less frail with stronger grip despite increased adiposity. [1]
The source at a glance
- Study type / format
- Animal survival study (abstract)
- Population / context
- GHA transgenic mice, including a separate cohort of 2-year-old mice
- Summary based on
- Study abstract
- Original publication
- September 1, 2026
Why a mouse model replaced Pegvisomant testing
The abstract states that disrupting growth hormone action is among the most potent known ways to extend lifespan, and that growth hormone receptor antagonists are potential healthspan therapeutics. Pegvisomant (Somavert) is described as the only FDA-approved such antagonist, used in acromegaly. Because it binds rodent receptors poorly, it has not been tested for lifespan extension in rodents. The authors therefore studied GHA transgenic mice, a line kept in their lab since 1991 and central to Pegvisomant's development.
Supporting source [1]
Survival and frailty in male and female GHA mice
The abstract reports that median and maximal lifespan were significantly increased in male GHA mice (p = 0.044 and p = 0.0037) and in female GHA mice (p = 2 × 10 and p = 9 × 10, as printed). Maximal lifespan rose by 186 days in males and 265 days in females. In a separate cohort of 2-year-old mice, GHA males and females were less frail and had stronger grip strength despite increased adiposity. The authors say a prior study with several limitations had not detected lifespan extension; the current study addressed those limitations.
Supporting source [1]
What the abstract does and does not establish
The authors conclude that growth hormone antagonism can improve health and extend lifespan, described as a first. This is an abstract of a mouse study: the animals were transgenic GHA mice, not people, and Pegvisomant itself was not tested for lifespan in rodents. The abstract does not report sample sizes, husbandry details or the full statistical approach, and the full text was not reviewed. The findings are associations in a model, not proof that a drug extends human lifespan.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The abstract does not report sample sizes, follow-up details or the full statistical approach, and the results come from transgenic mice, not humans.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
List EO, Berryman DE, Lach GS, Minto DF, Weese K, Kopchick JJ. · europepmc.org · September 1, 2026